Search results
Excessive table salt linked to a higher risk of stomach cancer
TheGrio via Yahoo News· 4 days agoAdditionally, Black men generally exhibit lower five-year survival rates across various cancer...
7 Kittens Founds Abandoned in Parking Lot Find Safety in Foster Home
PetHelpful via Yahoo News· 19 hours agoKittens under a month old have a very low survival rate without their mother. That is because they...
Bellwright impressions: still a long way to go
Sports Illustrated· 4 days agoBellwright is yet another survival crafting game with automation as its selling point, joining Palworld and The Forest 2, in their mission to scrub out...
We know apocalypse is coming - we've hoarded YEARS worth of weapons & food
The US Sun· 5 days agoA COUPLE preparing for an apocalypse revealed how they stockpile years' worth of food and weapons to...
Halle Berry explains the horrors of her upcoming movie Never Let Go: 'Is everything real or not?'...
Entertainment Weekly· 1 day agoJenkins and Percy Daggs IV, respectively), in a post-apocalyptic America. In the new trailer, below,...
US FDA approves Amgen drug for small cell lung cancer
Reuters via Yahoo News· 18 hours agoThe drug, marketed under the name Imdelltra, is part of Amgen's pipeline of bispecific antibodies...
Horseshoe crabs also nest in marshes, research finds
The Times and Democrat· 1 hour agoIf you’ve ever encountered the domed shell of a horseshoe crab, chances are it was on a sandy beach. Until recently, beaches were believed to be the only...
After 12 days, South Africa ends rescue efforts at collapsed building with 33 dead, 19 still missing
San Antonio Express-News· 3 hours agoAn exhaustive rescue operation to find missing construction workers trapped in the rubble of a...
Who chooses the animals that live at OKC Zoo? Meet the zoo's chief of animal programs
The Oklahoman via Yahoo News· 1 day agoThat is 100% not true. We do have close working relationships with them because they do have to...
FDA Approves Tarlatamab for Extensive-Stage SCLC
Medscape· 1 day agoContinued approval of the first-in-class bispecific T-cell engager (BiTE) may depend on proof of clinical benefit.